IGF2 Primary Antibody
|Aliases||IGF-II; PP9974; C11orf43; FLJ22066; FLJ44734|
|Formulation||Purified antibody in PBS with 0.05% sodium azide|
|Immunogen||Purified recombinant fragment of human IGF2 (AA: 25-180) expressed in E. Coli.|
|Shipping Information||This product will ship in a box containing blue ice at a temperature of 4°C. Learn More|
|ICC (Immunocytochemistry)||1/200 - 1/1000|
|IHC_P(Immunohistochemistry)||1/200 - 1/1000|
|FCM (Flow Cytometry)||1/200 - 1/400|
|WB (Western Blot)||1/500 - 1/2000|
Contact us to order
Figure 1: Western blot analysis using IGF2 mAb against human IGF2 recombinant protein. (Expected MW is 43.1 kDa)
Figure 2: Western blot analysis using IGF2 mAb against HEK293 (1) and IGF2 (AA: 25-180)-hIgGFc transfected HEK293 (2) cell lysate.
Figure 3: Immunofluorescence analysis of HeLa cells using IGF2 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.
Figure 4: Flow cytometric analysis of HepG2 cells using IGF2 mouse mAb (green) and negative control (red).
Figure 5: Immunohistochemical analysis of paraffin-embedded ovarian cancer tissues using IGF2 mouse mAb with DAB staining.
Figure 6: Immunohistochemical analysis of paraffin-embedded bladder cancer tissues using IGF2 mouse mAb with DAB staining.
Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);
This gene encodes a member of the insulin family of polypeptide growth factors, which are involved in development and growth. It is an imprinted gene, expressed only from the paternal allele, and epigenetic changes at this locus are associated with Wilms tumour, Beckwith-Wiedemann syndrome, rhabdomyosarcoma, and Silver-Russell syndrome. A read-through INS-IGF2 gene exists, whose 5' region overlaps the INS gene and the 3' region overlaps this gene. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.
|References (references)||1.Biomarkers. 2011 Jun;16(4):346-54. 2.J Cancer Res Clin Oncol. 2011 Feb;137(2):339-45.|